BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline
· seekingalpha.com
BlossomHill Therapeutics’ $125M IPO: EGFR-mutant NSCLC pipeline, BH-30643 early data, Phase 2 funding and upside to $16/share—read now.
Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs.He also leads the investing group IPO E...